---
title: "Lysergide (DT120) in Generalized anxiety disorder: Prevalence"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Prevalence. Topics: United States past-year prevalence by clinical interview: MDPS, adults aged 18 to 65, 2020 to 2022; United States diagnosed prevalence: Komodo Healthcare Map claims, adults, 2020 to 2023; United States past-year and lifetime prevalence: NCS-R, adults, 2001 to 2003; United States 12-month prevalence and severity: NCS-R, adults (n=9282); 13 further topics. 17 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/prevalence"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Generalized anxiety disorder

<a id="topic-2.2.1.2.2-1"></a>

### United States past-year prevalence by clinical interview: MDPS, adults aged 18 to 65, 2020 to 2022

> “The study sample included adults aged 18 to 65 residing in households, prisons, homeless shelters, and state psychiatric hospitals in the United States.”
> “Clinical interviews were conducted with close to 5,700 participants, virtually or in person, between October 2020 and October 2022.”
> “The two most common mental disorders among adults aged 18 to 65 were major depressive disorder (15.5 percent, or approximately 31.4 million adults) and generalized anxiety disorder (10.0 percent, or approximately 20.2 million adults). These prevalence rates are much higher than reported by prior studies.”

Source: [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report)

> “GAD, 10.0 percent (95 percent CI: 8.3 to 12.1 percent)”
> “As shown in Figure 3.B.2, the most common disorders, MDD and GAD, along with OCD and bipolar I disorder, occurred the most frequently in young adults aged 18 to 25.”
> “The MDPS prevalence rates for MDD (15.5 percent) and GAD (10.0 percent) were substantially higher than rates in past nationally representative studies. The most obvious explanation is that the MDPS was conducted during the COVID-19 pandemic.”

Source: [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf)

<a id="topic-2.2.1.2.2-2"></a>

### United States diagnosed prevalence: Komodo Healthcare Map claims, adults, 2020 to 2023

> “Projected annual prevalence increased from 5.4% in 2020–6.6% in 2023, with a 3-year prevalence of 10.3% over the 2021–2023 period.”
> “Importantly, more than one in ten adults met criteria for GAD over a three-year period, exceeding lifetime prevalence estimates from prior general population studies, which have ranged from approximately 5% to almost 8%”
> “When this exclusion criterion was removed, the estimated one-year prevalence of GAD in 2023 increased from 6.6% in the base case to 7.2%.”
> “Demographic analyses across each 1-year time period reveal that females appeared in GAD claims data at more than twice the rate of males.”

Source: [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/)

<a id="topic-2.2.1.2.2-3"></a>

### United States past-year and lifetime prevalence: NCS-R, adults, 2001 to 2003

> “Based on diagnostic interview data from National Comorbidity Survey Replication (NCS-R), Figure 1 shows past year prevalence of generalized anxiety disorder among U.S. adults aged 18 or older.”
> “An estimated 2.7% of U.S. adults had generalized anxiety disorder in the past year.”
> “Past year prevalence of generalized anxiety disorder among adults was higher for females (3.4%) than for males (1.9%).”
> “An estimated 5.7% of U.S. adults experience generalized anxiety disorder at some time in their lives”
> “An estimated 32.3% had serious impairment, 44.6% had moderate impairment, and 23.1% had mild impairment.”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.2.2-4"></a>

### United States 12-month prevalence and severity: NCS-R, adults (n=9282)

| Generalized anxiety disorder, 12-month | Total, % (se) | Serious, % (se) | Moderate, % (se) | Mild, % (se) |
| --- | --- | --- | --- | --- |
| NCS-R | “3.1 (0.2)” | “32.3 (2.9)” | “44.6 (4.0)” | “23.1 (2.9)” |

Source: [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)

> “Anxiety disorders are the most prevalent class (18.1%), followed by mood disorders (9.5%), impulse-control disorders (8.9%), and substance disorders (3.8%).”

Source: [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)

<a id="topic-2.2.1.2.2-5"></a>

### United States lifetime prevalence and lifetime morbid risk: NCS-R and NCS-A, ages 13 and older

> “The LMR/12‐month prevalence estimates ranked by frequency are as follows: major depressive episode: 29.9%/8.6%; specific phobia: 18.4/12.1%; social phobia: 13.0/7.4%; post‐traumatic stress disorder: 10.1/3.7%; generalized anxiety disorder: 9.0/2.0%”
> “The less common anxiety disorders include GAD (4.3%), panic disorder with or without agoraphobia (PD; 3.8%), agoraphobia with or without panic disorder (2.5%), and OCD (2.3%).”
> “These discrepancies might reflect the fact that GAD has a chronic‐episodic course reflected in intermediate prevalence ratios for all three age groups (roughly 35–50% of lifetime cases in episode in the 12 months before interview)”

Source: [Kessler et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4005415/)

<a id="topic-2.2.1.2.2-6"></a>

### United States 12-month and lifetime prevalence: NESARC, adults

> “Prevalences of 12-month and lifetime GAD were 2.1% and 4.1%.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

<a id="topic-2.2.1.2.2-7"></a>

### United States adolescent lifetime prevalence: NCS-A, ages 13 to 18, 2001 to 2004

> “Based on diagnostic interview data from National Comorbidity Survey Adolescent Supplement (NCS-A), Figure 3 shows lifetime prevalence of generalized anxiety disorder among U.S. adolescents aged 13-18”
> “An estimated 2.2% of adolescents had generalized anxiety disorder, and an estimated 0.9% had severe impairment.”
> “The prevalence of generalized anxiety disorder among adolescents was higher for females (3.0%) than for males (1.5%).”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.2.2-8"></a>

### United States primary care prevalence: 15 clinics, 2004 to 2005

> “15 U.S. primary care clinics.”
> “Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder”

Source: [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)

<a id="topic-2.2.1.2.2-9"></a>

### Cross-national prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, 26 countries, 2001 to 2012

> “Across all surveys, the combined lifetime prevalence of GAD was 3.7%, 12-month prevalence was 1.8%, and 30-day prevalence was 0.8% (Table 1). Lifetime prevalence estimates varied widely across countries, ranging from less than 1% of the populations of Nigeria and Shenzhen, China, to approximately 8% of the populations of Australia, New Zealand, and the United States. Prevalence increased with economic development: lifetime estimates (SE) were lowest in low-income (1.6% [0.1%]), moderate in middle-income (2.8% [0.1%]), and highest in high-income (5.0% [0.1%]) countries.”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.2.2-10"></a>

### United States prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, US survey (n=9282)

| Country | Lifetime prevalence, No. (%) [SE] | 12-mo prevalence, No. (%) [SE] | 30-d prevalence, No. (%) [SE] | 12-mo prevalence among lifetime cases, No. (%) [SE] |
| --- | --- | --- | --- | --- |
| United States | “752 (7.8) [0.3]” | “394 (4.0) [0.2]” | “157 (1.6) [0.2]” | “394 (52.1) [1.8]” |

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.2.2-11"></a>

### Sponsor-stated number of United States adults with generalized anxiety disorder

> “Generalized anxiety disorder, or GAD, is one of the most common psychiatric disorders, affecting approximately 26 million U.S. adults”
> “Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings report. RTI International and current U.S. Census data and internal company estimates.”

Source: [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)

> “GAD is one of the most common psychiatric disorders, affecting approximately 26 million U.S. adults”

Source: [Definium Therapeutics Wired for Worry announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/238/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology)

<a id="topic-2.2.1.2.2-12"></a>

### Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019

> “The GAD–7 scale is a validated brief self-report measure to screen for GAD and assess the severity of symptoms”
> “Adults with GAD–7 scores of 0–4 are considered to have no or minimal symptoms of GAD, while those with scores of 5–9, 10–14, or 15–21 are considered to have mild, moderate, or severe symptoms, respectively”
> “During 2019, 9.5%, 3.4%, and 2.7% of adults experienced mild, moderate, or severe symptoms of anxiety in the past 2 weeks, respectively, while 84.4% experienced no or minimal symptoms.”
> “The total percentage of adults who experienced any anxiety symptoms in the past 2 weeks decreased with age, from 19.5% among adults aged 18–29, 16.6% among adults aged 30–44, 15.2% among adults aged 45–64, to 11.2% among adults aged 65 and over (Figure 2).”
> “A total of 19.0% of women experienced anxiety symptoms in the past 2 weeks that were either mild, moderate, or severe, compared with 11.9% of men (Figure 3).”

Source: [Terlizzi and Villarroel (2020)](https://www.cdc.gov/nchs/products/databriefs/db378.htm)

<a id="topic-2.2.1.2.2-13"></a>

### Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019 and 2022

> “During 2022, about one in five adults age 18 and older experienced any symptoms of anxiety (18.2%) or symptoms of depression (21.4%) in the past 2 weeks.”
> “A significant increase was seen in the percentage of adults with anxiety symptoms (from 15.6% to 18.2%, respectively) and depression symptoms (from 18.5% to 21.4%, respectively) between 2019 and 2022.”

Source: [Terlizzi and Zablotsky (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11616099/)

<a id="topic-2.2.1.2.2-14"></a>

### Positive GAD-7 screen, score of 10 or more (symptoms, not diagnosis): CLIMB cohort, United States adults, 2020 to 2022

> “Using a longitudinal, nationally representative study of US adults, we used generalized estimating equations to estimate the burden of positive screen for GAD (GAD-7 score ≥ 10) over time. The final sample included 1270 adults at least 18 years old who completed the COVID-19 and Life Stressors Impact on Mental Health and Well-being (CLIMB) Study, with data collected in spring 2020, 2021, and 2022. The national prevalence of positive screen for GAD decreased from 24.4% in 2020 to 21.3% in 2022 (P < .05).”

Source: [Ettman et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39123097/)

<a id="topic-2.2.1.2.2-15"></a>

### Self-reported past-month nervousness (single item, not diagnosis): NSDUH, United States adults, 2008 to 2018

> “This variable was assessed with the item”
> “how often did you feel nervous during the past 30 days”
> “Anxiety increased from 5.12% in 2008 to 6.68% in 2018 (p < 0.0001) among adult Americans. Stratification by age revealed the most notable increase from 7.97% to 14.66% among respondents 18–25 years old (p < 0.001)”

Source: [Goodwin et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7441973/)

<a id="topic-2.2.1.2.2-16"></a>

### Global prevalence of anxiety disorders (all types combined): Global Burden of Disease Study 2019

> “The accumulated anxiety disorder patients worldwide increased from 194.92 (95% UI: 165.10, 231.23) million in 1990 to 301.39 (95% UI: 252.63, 356.00) million in 2019, and kept a stable ASPR with around 37.8 (95% UI: 31.94, 44.77) per 1000 population during the period”

Source: [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)

<a id="topic-2.2.1.2.2-17"></a>

### Global prevalence of anxiety disorders (all types combined) in 2020: change attributed to the COVID-19 pandemic

> “We also estimated an additional 76·2 million (64·3 to 90·6) cases of anxiety disorders globally (an increase of 25·6% [23·2 to 28·0]), such that the total prevalence was 4802·4 cases (4108·2 to 5588·6)”

Source: [COVID-19 Mental Disorders Collaborators (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500697/)

Additional sources: [Kessler et al. (2005a)](https://pubmed.ncbi.nlm.nih.gov/15939837/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
